Monoclonal antibodies (mAbs) are blood proteins that neutralize a specific antigen detected by the body.
mAbs are designed to bind to a single target, making them a potent mode for developing precision medicines. The specificity of monoclonal antibodies makes them a critical component of the multimodal approach at Gemini Therapeutics.